Central nervous system infection caused by vancomycin-intermediate Staphylococcus aureus (SCCmec type IV, ST8).

[1]  M. Yano,et al.  The emerging ST8 methicillin-resistant Staphylococcus aureus clone in the community in Japan: associated infections, genetic diversity, and comparative genomics. , 2015, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[2]  L. Cui,et al.  Comprehensive Identification of Mutations Responsible for Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA)-to-VISA Conversion in Laboratory-Generated VISA Strains Derived from hVISA Clinical Strain Mu3 , 2013, Antimicrobial Agents and Chemotherapy.

[3]  Ronald N. Jones,et al.  Evaluation of Vancomycin Susceptibility Testing for Methicillin-Resistant Staphylococcus aureus: Comparison of Etest and Three Automated Testing Methods , 2013, Journal of Clinical Microbiology.

[4]  宏文 戸田,et al.  グリコペプチド系抗菌薬を投与中に検出されたvancomycin intermediate Staphylococcus aureus の臨床微生物学的解析 , 2012 .

[5]  G. Wakabayashi,et al.  Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[6]  D. Follmann,et al.  Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.

[7]  F. Lowy,et al.  Contribution of Selected Gene Mutations to Resistance in Clinical Isolates of Vancomycin-Intermediate Staphylococcus aureus , 2012, Antimicrobial Agents and Chemotherapy.

[8]  F. Pea,et al.  Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. , 2012, The Journal of antimicrobial chemotherapy.

[9]  Tetsuya Matsumoto,et al.  Epidemiological and microbiological analysis of community-associated methicillin-resistant Staphylococcus aureus strains isolated from a Japanese hospital. , 2012, Japanese journal of infectious diseases.

[10]  M. Kaku,et al.  Antimicrobial susceptibility and molecular characteristics of 857 methicillin-resistant Staphylococcus aureus isolates from 16 medical centers in Japan (2008-2009): nationwide survey of community-acquired and nosocomial MRSA. , 2012, Diagnostic microbiology and infectious disease.

[11]  Mamta Sharma,et al.  Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. , 2011, The Journal of antimicrobial chemotherapy.

[12]  S. Iwabuchi,et al.  Linezolid treatment for intracranial abscesses caused by methicillin-resistant Staphylococcus aureus--two case reports. , 2010, Neurologia medico-chirurgica.

[13]  L. Friedrich,et al.  Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. , 2007, The Journal of antimicrobial chemotherapy.

[14]  G. Barnaud,et al.  Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Xiao Xue Ma,et al.  Predominance of Clones Carrying Panton-Valentine Leukocidin Genes among Methicillin-Resistant Staphylococcus aureus Strains Isolated in Japanese Hospitals from 1979 to 1985 , 2006, Journal of Clinical Microbiology.

[16]  Xiao Xue Ma,et al.  Combination of Multiplex PCRs for Staphylococcal Cassette Chromosome mec Type Assignment: Rapid Identification System for mec, ccr, and Major Differences in Junkyard Regions , 2006, Antimicrobial Agents and Chemotherapy.

[17]  M. Aepfelbacher,et al.  Identification of the Staphylococcus aureus etd Pathogenicity Island Which Encodes a Novel Exfoliative Toxin, ETD, and EDIN-B , 2002, Infection and Immunity.

[18]  M. Aepfelbacher,et al.  Clonal association of Staphylococcus aureus causing bullous impetigo and the emergence of new methicillin-resistant clonal groups in Kansai district in Japan. , 2002, The Journal of infectious diseases.

[19]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.

[20]  A. Patchefsky,et al.  Case report 3 , 1976, Skeletal Radiology.

[21]  T. Miyara,et al.  [Clinical microbiological investigation of vancomycin intermediate Staphylococcus aureus during glycopeptide therapy]. , 2012, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[22]  Sara E Cosgrove,et al.  Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  山川 潤.  Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan : a retrospective study , 2011 .

[24]  K. Shimada,et al.  Antimicrobial susceptibility of pathogens isolated from more than 10 000 patients with infectious respiratory diseases: a 25-year longitudinal study , 2009, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[25]  P. Vanhems,et al.  Staphylococcus aureus, the major pathogen in orthopaedic and cardiac surgical site infections: a literature review. , 2008, International journal of surgery.

[26]  T. Nakae,et al.  Occurrence of vancomycin-intermediate-resistant Staphylococcus aureus in Japan , 2007, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[27]  B. Spratt,et al.  Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. , 2000, Journal of clinical microbiology.